These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10091998)

  • 1. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.
    Ling R; Harrison TJ
    J Gen Virol; 1999 Mar; 80 ( Pt 3)():601-606. PubMed ID: 10091998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
    Melegari M; Scaglioni PP; Wands JR
    Hepatology; 1998 Feb; 27(2):628-33. PubMed ID: 9462667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
    Allen MI; Deslauriers M; Andrews CW; Tipples GA; Walters KA; Tyrrell DL; Brown N; Condreay LD
    Hepatology; 1998 Jun; 27(6):1670-7. PubMed ID: 9620341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
    Ladner SK; Miller TJ; Otto MJ; King RW
    Antivir Chem Chemother; 1998 Jan; 9(1):65-72. PubMed ID: 9875378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus].
    Song JW; Lin JS; Kong XJ; Liang KH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):361-3. PubMed ID: 12837218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA.
    Ladner SK; Miller TJ; King RW
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2128-31. PubMed ID: 9687422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
    Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
    Delaney WE; Miller TG; Isom HC
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.
    Bock CT; Tillmann HL; Torresi J; Klempnauer J; Locarnini S; Manns MP; Trautwein C
    Gastroenterology; 2002 Feb; 122(2):264-73. PubMed ID: 11832441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
    Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
    J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
    León P; Pozo F; Echevarría JM
    Enferm Infecc Microbiol Clin; 2004 Mar; 22(3):133-7. PubMed ID: 14987532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.
    Ogata N; Ichida T; Aoyagi Y; Kitajima I
    Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K; Suzuki Y; Kobayashi M; Kobayashi M; Tsubota A; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Murashima N; Ikeda K; Kumada H
    Hepatology; 1998 Jun; 27(6):1711-6. PubMed ID: 9620347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.
    Jardi R; Buti M; Rodriguez-Frias F; Cotrina M; Costa X; Pascual C; Esteban R; Guardia J
    J Virol Methods; 1999 Dec; 83(1-2):181-7. PubMed ID: 10598095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection.
    Ono-Nita SK; Kato N; Shiratori Y; Masaki T; Lan KH; Carrilho FJ; Omata M
    Hepatology; 1999 Mar; 29(3):939-45. PubMed ID: 10051501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.